This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Spinifex Receives $1.5m In R&D Tax Incentive For Research Activities Related To The Discovery Of Treatments For Pain

MELBOURNE, Australia, March 27, 2013 /PRNewswire/ --

Spinifex Pharmaceuticals, an Australian pain drug development company, today announces it has received an approximately AUS$1.5 million R&D tax incentives cash refund for research activities relating to the discovery of new drugs for the treatment and management of pain. The R&D Incentive Program is an annual scheme, jointly administered by AusIndustry and the Australian Taxation Office, which enables Spinifex to apply for it in subsequent years.

The funds will be reinvested in further clinical development of the Company's lead candidate, EMA401, an AT 2 receptor antagonist for the treatment of chronic pain, including neuropathic pain. Spinifex reported positive results of its Phase 2 study of EMA401 in post-herpetic neuralgia (PHN) in Q3 of last year, and more recently initiated a Phase 2 proof-of-concept study in chemotherapy-induced peripheral neuropathy (CIPN).

The market for neuropathic pain treatments is expected to continue to increase and is projected to reach US$6.2 billion by 2017. Despite being a large and growing market, current therapy for chronic and neuropathic pain needs to be improved as a significant proportion of patients don't respond to current therapy and these treatments have dose-limiting side effects. As a result, EMA401 is being developed as a potential first-in-class oral treatment for chronic pain, including neuropathic pain, without central nervous system side effects.

Spinifex Pharmaceuticals CEO Tom McCarthy said: "This payment under the R&D tax incentive program is a good example of how Government initiatives can support innovative companies in the biotechnology industry and other sectors. These additional funds are welcome and we look forward to their contributing to our continued clinical development of EMA401 for the treatment of chronic and neuropathic pain indications. In addition to this payment, we continue to expand our non-clinical activities with the support of our existing investors."

As described above EMA401 is an AT 2 receptor antagonist. The discovery that AT 2 receptor antagonists offer an innovative approach to the treatment of neuropathic and inflammatory pain was originally made by Professor Maree Smith at The University of Queensland. Having acquired the technology, Spinifex has conducted a comprehensive pre-clinical and early clinical development program on EMA401. Spinifex continues to conduct research into the role of the AT 2 receptor in nociceptive, inflammatory and neuropathic pain states and these fundamental studies support not only the EMA401 clinical program but also Spinifex's ongoing AT 2 receptor antagonist drug discovery program.

Spinifex Pharmaceuticals

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs